Long-Acting Treatments for Hepatitis B

Area of Science:

• Pharmacology and Drug Development
• Virology and Infectious Diseases
• Hepatology

Background:

• An estimated 257 million individuals worldwide live with chronic hepatitis B virus (HBV) infection.
• Existing treatments for chronic HBV infection require frequent administration, posing adherence challenges.
• The development of long-acting antiviral formulations offers a potential solution to improve treatment adherence and efficacy.

Purpose of the Study:

• To review the potential applications of long-acting antiviral compounds for chronic hepatitis B.
• To assess the progress and challenges in developing injectable and implantable long-acting anti-HBV medications.
• To highlight advancements in dual-acting agents targeting both hepatitis B virus (HBV) and human immunodeficiency virus (HIV).

Main Methods:

• Review of current research and development in long-acting antiviral formulations for HBV.
• Analysis of injection and implant-based delivery systems for anti-HBV derivates (e.g., tenofovir, entecavir).
• Examination of progress in developing dual-acting compounds against HBV and HIV.

Main Results:

• Significant progress has been made in formulating long-acting tenofovir-based medications.
• These tenofovir-based medications demonstrate dual activity against both human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
• Both injection and implant approaches are being explored for delivering long-acting antiviral compounds.

Conclusions:

• Long-acting antiviral compounds represent a promising therapeutic strategy for chronic hepatitis B.
• Dual-acting agents targeting HBV and HIV show significant potential for improved patient management.
• Overcoming substantial formulation and delivery challenges is critical for the clinical availability of these advanced HBV therapies.